Design, synthesis, and biological evaluation of quinoxalinone derivatives as potent BRD4 inhibitors
[Display omitted] •Novel quinoxalinone derivatives as BRD4 inhibitors were designed and synthesized.•Compound X9 manifested promising BRD4 inhibitory activity (IC50 = 82.3 nM).•Compound X9 exhibited superior anti-proliferative activity to HepG2 cell line.•Compound X9 displayed good inhibitory effect...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry 2023-01, Vol.78, p.117152, Article 117152 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | [Display omitted]
•Novel quinoxalinone derivatives as BRD4 inhibitors were designed and synthesized.•Compound X9 manifested promising BRD4 inhibitory activity (IC50 = 82.3 nM).•Compound X9 exhibited superior anti-proliferative activity to HepG2 cell line.•Compound X9 displayed good inhibitory effects on the migration and c-Myc protein in HepG2 cell line.
The bromodomain-containing protein 4 (BRD4) has gained growing interest as an effective drug target for the treatment of hepatocellular carcinoma (HCC). Herein, we designed and synthesized a series of quinoxalinone derivatives as BRD4 inhibitors via scaffold hopping. The representative compound X9 showed potent BRD4 inhibitory activity (with IC50 = 82.3 nM), and preferable antiproliferative activity against HepG2 cells (with IC50 = 1.13 ± 0.07 μM), as well as less toxicity against GES-1 cells (with IC50 = 57.24 ± 5.46 μM). Furthermore, compound X9 dose-dependently inhibited colony formation and blocked the migration of HepG2 cells by down-regulating the expression of Snail and MMP-9 while up-regulating the E-cadherin and Occludin. Besides, compound X9 efficiently down-regulated the expression of c-Myc in HepG2 cells, induced apoptosis, and arrested at G0/G1 phase. In total, quinoxalinone was a potential core as BRD4 inhibitor and compound X9 might be effective for liver cancer therapy. |
---|---|
ISSN: | 0968-0896 1464-3391 |
DOI: | 10.1016/j.bmc.2022.117152 |